查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586371

肺炎鏈球菌疫苗市場、規模、佔有率、趨勢、行業分析報告：按疫苗類型、按產品類型、按最終用戶、按地區、按細分市場、預測，2024-2032 年

Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By End User; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據Polaris Market Research的最新研究，到2032年，全球肺炎鏈球菌疫苗市場預計將達到144.3億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

由於人們對肺炎球菌感染的認識不斷提高以及政府資助的免疫計劃的擴大，肺炎球菌疫苗市場正在經歷顯著增長。隨著公共衛生運動強調肺炎球菌疾病（包括肺炎和腦膜炎）的風險，個人和醫療保健提供者越來越多地尋求疫苗接種。此外，世界各國政府正在實施強有力的免疫舉措，旨在改善社區健康並降低與肺炎球菌感染相關的醫療費用。這些計劃通常包括贈款和教育資源，使服務不足的人更容易獲得疫苗。隨著意識的不斷提高和疫苗接種工作的加強，對肺炎球菌疫苗的需求預計將大幅增加，對肺炎球菌疫苗市場的成長產生積極影響。

肺炎鏈球菌疫苗市場是由促進廣泛接種疫苗的政府措施和衛生政策所推動的。這些計劃旨在透過減少肺炎和腦膜炎等肺炎球菌疾病的發生率來改善公共衛生。隨著各國政府實施全面的免疫策略，包括資金和宣傳活動，獲得疫苗的機會將會改善，進而提高疫苗接種率。

生物技術和市場參與者之間不斷發展的合作夥伴關係旨在開發更有效的肺炎球菌結合疫苗 (PCV)，這將推動未來幾年肺炎球菌疫苗市場的成長。例如，2023年6月，SK Bioscience與Sanofi合作開發了GBP410，這是一種21價PCV，在嬰兒和嬰幼兒的2期試驗中顯示出正面結果。同樣，2024 年 3 月，Pfizer的 20 價 PCV PREVENAR 20 獲得歐盟委員會批准，用於歐洲和世界各地的嬰兒、兒童和青少年疫苗接種。此類策略聯盟將加強研究能力、加速市場准入並擴大疫苗准入範圍，最終推動預計的多年市場成長。

肺炎鏈球菌疫苗市場報告亮點

肺炎鏈球菌多醣體疫苗 (PPV) 細分市場在 2023 年佔據最大的市場佔有率，這主要是由於其全球接受度高且易於取得。

肺炎鏈球菌結合疫苗 (PCV) 領域預計將在研究期間出現最高成長，因為 PCV 涵蓋肺炎鏈球菌範圍更廣。

Prevnar 13因其適合廣泛的年齡層和更有效的治療而在2023年佔據最大的市場佔有率。

由於對肺炎球菌疫苗開發的投資增加，預計亞太地區將在研究期間實現最快的成長。

全球公司包括GSK plc、Pfizer Inc、Merck、Serum Institute、CSL Ltd.、Sanofi。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第四章全球肺炎鏈球菌疫苗市場洞察

  • 市場快照
  • 肺炎鏈球菌疫苗市場動態
    • 促進因素和機會
      • 所有年齡層的肺炎球菌感染發生率不斷上升推動市場成長
      • 促進廣泛疫苗接種的衛生政策正在推動市場規模擴大
    • 抑制因素和課題
      • 監理障礙
  • PESTEL 分析
  • 肺炎鏈球菌疫苗市場趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第五章全球肺炎鏈球菌疫苗市場：依疫苗類型劃分

  • 主要發現
  • 簡介
  • 肺炎鏈球菌結合疫苗
  • 肺炎鏈球菌多醣體疫苗

第 6 章全球肺炎鏈球菌疫苗市場：依產品

  • 主要發現
  • 簡介
  • Prevenar 13
  • Synflorix
  • Pneumovax 23
  • 其他產品

第 7 章全球肺炎鏈球菌疫苗市場：依最終使用者劃分

  • 主要發現
  • 簡介
  • 公共部門
  • 私部門

第 8 章全球肺炎鏈球菌疫苗市場：按地區

  • 主要發現
  • 簡介
    • 肺炎鏈球菌疫苗市場評估：地區，2019-2032
  • 北美
    • 北美：依疫苗類型劃分，2019-2032 年
    • 北美：依產品分類，2019-2032 年
    • 北美：依最終使用者劃分，2019-2032 年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依疫苗類型劃分，2019-2032 年
    • 歐洲：依產品分類，2019-2032 年
    • 歐洲：依最終使用者劃分，2019-2032 年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 歐洲其他地區
  • 亞太地區
    • 亞太地區：依疫苗類型劃分，2019-2032 年
    • 亞太地區：依產品分類，2019-2032 年
    • 亞太地區：依最終使用者劃分，2019-2032 年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳大利亞
    • 亞太地區其他地區
  • 中東/非洲
    • 中東和非洲：依疫苗類型劃分，2019-2032 年
    • 中東與非洲：依產品分類，2019-2032 年
    • 中東和非洲：按最終用戶劃分，2019-2032 年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東/非洲
  • 拉丁美洲
    • 拉丁美洲：依疫苗類型劃分，2019-2032 年
    • 拉丁美洲：依產品分類，2019-2032 年
    • 拉丁美洲：依最終使用者劃分，2019-2032 年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協定/揭露

第十章公司簡介

  • GSK plc
  • Pfizer Inc.
  • Merck KGaA
  • Serum Institute of India Pvt. Ltd.
  • CSL Ltd.
  • Sanofi S.A
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd
  • Johnson & Johnson
  • AstraZeneca
  • Novavax
Product Code: PM5107

The global pneumococcal vaccine market size is expected to reach USD 14.43 billion by 2032, according to a new study by Polaris Market Research. The report "Pneumococcal Vaccine Market Share, Size, Trends, Industry Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine); By Product Type; By Distribution Channel; By Region; Segment Forecast, 2024-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The pneumococcal vaccine market is experiencing significant growth driven by increased awareness about pneumococcal infections and the expansion of government-sponsored immunization programs. As public health campaigns highlight the dangers of pneumococcal disease, including pneumonia and meningitis, individuals and healthcare providers are more inclined to seek vaccination. Additionally, governments worldwide are implementing robust immunization initiatives aimed at enhancing community health and reducing healthcare costs associated with pneumococcal diseases. These programs often include subsidies and educational resources, making vaccines more accessible to underserved populations. As awareness continues to rise and vaccination efforts intensify, the demand for pneumococcal vaccines is expected to increase substantially, impacting the pneumococcal vaccine market growth positively.

The pneumococcal vaccine market is driven by government initiatives and health policies that promote widespread vaccination. These programs aim to enhance public health by reducing the incidence of pneumococcal diseases, such as pneumonia and meningitis. As governments implement comprehensive immunization strategies, including funding and awareness campaigns, accessibility to vaccines improves, leading to higher vaccination rates.

Increasing partnerships between biotech firms and market players aimed at developing more effective pneumococcal conjugate vaccines (PCVs) are fueling the pneumococcal vaccine market growth in forecast years. For Instance, in June 2023, SK Bioscience collaborated with Sanofi to create GBP410, a 21-valent PCV that demonstrated positive results in Phase 2 studies involving toddlers and infants. Similarly, in March 2024, Pfizer's PREVENAR 20, a 20-valent PCV, received approval from the European Commission to immunize infants, children, and adolescents across Europe and globally. These strategic alliances enhance research capabilities, expedite development timelines, and expand vaccine access, ultimately driving market growth during projected years.

Pneumococcal Vaccine Market Report Highlights

The pneumococcal polysaccharide vaccine (PPV) segment accounted for the largest market share in 2023 primarily due to global acceptance and easy availability.

The Pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, as PCV covers more range of the streptococcus pneumoniae.

The Prevnar 13 segment accounted for the largest market share in 2023, as it caters to a wider range of age, and is more efficient in treating the disease.

The Asia Pacific is projected to register the fastest growth over the study period, attributable to the increasing investment in pneumococcal vaccine development.

The global players are GSK plc, Pfizer Inc, Merck, Serum Institute, CSL Ltd., and Sanofi.

Polaris Market Research has segmented the pneumococcal vaccine market report based on vaccine type, product type, distribution channel, and region:

By Vaccine Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Pneumococcal conjugate vaccine (PCV)
  • Pneumococcal polysaccharide vaccine (PPV)

By Product Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Prevnar 13
  • Synflorix
  • Pneumovax23

By Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Distribution partner companies
  • Non-governmental Organizations
  • Government Authorities

By Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Vaccine Types
    • 3.2.1. Primary Vaccine Types
    • 3.2.2. Secondary Vaccine Types

4. Global Pneumococcal Vaccine Market Insights

  • 4.1. Pneumococcal Vaccine Market - Market Snapshot
  • 4.2. Pneumococcal Vaccine Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Pneumococcal Disease Across All Age Groups is Driving Market Growth
      • 4.2.1.2. Health Policies Promoting Widespread Vaccination is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Regulatory Hurdles
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pneumococcal Vaccine Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pneumococcal Vaccine Market, by Vaccine Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • 5.3. Pneumococcal conjugate vaccine
    • 5.3.1. Global Pneumococcal Vaccine Market, by Pneumococcal conjugate vaccine, by Region, 2019-2032 (USD billion)
  • 5.4. Pneumococcal polysaccharide vaccine
    • 5.4.1. Global Pneumococcal Vaccine Market, by Pneumococcal polysaccharide vaccine, by Region, 2019-2032 (USD billion)

6. Global Pneumococcal Vaccine Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • 6.3. Prevnar 13
    • 6.3.1. Global Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
  • 6.4. Synflorix
    • 6.4.1. Global Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
  • 6.5. Pneumovax23
    • 6.5.1. Global Pneumococcal Vaccine Market, by Pneumovax23, by Region, 2019-2032 (USD billion)
  • 6.6. Other Product
    • 6.6.1. Global Pneumococcal Vaccine Market, by Other Product, by Region, 2019-2032 (USD billion)

7. Global Pneumococcal Vaccine Market, by End User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 7.3. Public Sector
    • 7.3.1. Global Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
  • 7.4. Private Sector
    • 7.4.1. Global Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Global Pneumococcal Vaccine Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • 8.3. Pneumococcal Vaccine Market - North America
    • 8.3.1. North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.3.2. North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.3.3. North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.4. Pneumococcal Vaccine Market - U.S.
      • 8.3.4.1. U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.4.2. U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.4.3. U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.3.5. Pneumococcal Vaccine Market - Canada
      • 8.3.5.1. Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.3.5.2. Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.3.5.3. Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.4. Pneumococcal Vaccine Market - Europe
    • 8.4.1. Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.4.2. Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.4.3. Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.4. Pneumococcal Vaccine Market - UK
      • 8.4.4.1. UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.4.3. UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.5. Pneumococcal Vaccine Market - France
      • 8.4.5.1. France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.5.3. France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.6. Pneumococcal Vaccine Market - Germany
      • 8.4.6.1. Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.6.3. Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.7. Pneumococcal Vaccine Market - Italy
      • 8.4.7.1. Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.7.3. Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.8. Pneumococcal Vaccine Market - Spain
      • 8.4.8.1. Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.8.3. Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.9. Pneumococcal Vaccine Market - Netherlands
      • 8.4.9.1. Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.9.3. Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.10. Pneumococcal Vaccine Market - Russia
      • 8.4.10.1. Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.10.3. Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.4.11. Pneumococcal Vaccine Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.4.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.4.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.5. Pneumococcal Vaccine Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.5.2. Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.5.3. Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.4. Pneumococcal Vaccine Market - China
      • 8.5.4.1. China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.4.2. China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.4.3. China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.5. Pneumococcal Vaccine Market - India
      • 8.5.5.1. India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.5.2. India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.5.3. India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.6. Pneumococcal Vaccine Market - Malaysia
      • 8.5.6.1. Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.6.2. Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.6.3. Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.7. Pneumococcal Vaccine Market - Japan
      • 8.5.7.1. Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.7.2. Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.7.3. Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.8. Pneumococcal Vaccine Market - Indonesia
      • 8.5.8.1. Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.8.2. Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.8.3. Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.9. Pneumococcal Vaccine Market - South Korea
      • 8.5.9.1. South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.9.2. South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.9.3. South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.10. Pneumococcal Vaccine Market - Australia
      • 8.5.10.1. Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.10.2. Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.10.3. Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.5.11. Pneumococcal Vaccine Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.6. Pneumococcal Vaccine Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.6.2. Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.6.3. Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.4. Pneumococcal Vaccine Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.4.2. Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.4.3. Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.5. Pneumococcal Vaccine Market - UAE
      • 8.6.5.1. UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.5.2. UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.5.3. UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.6. Pneumococcal Vaccine Market - Israel
      • 8.6.6.1. Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.6.2. Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.6.3. Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.7. Pneumococcal Vaccine Market - South Africa
      • 8.6.7.1. South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.7.2. South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.7.3. South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.6.8. Pneumococcal Vaccine Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • 8.7. Pneumococcal Vaccine Market - Latin America
    • 8.7.1. Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
    • 8.7.2. Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
    • 8.7.3. Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.4. Pneumococcal Vaccine Market - Mexico
      • 8.7.4.1. Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.4.2. Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.4.3. Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.5. Pneumococcal Vaccine Market - Brazil
      • 8.7.5.1. Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.5.2. Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.5.3. Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.6. Pneumococcal Vaccine Market - Argentina
      • 8.7.6.1. Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.6.2. Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.6.3. Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
    • 8.7.7. Pneumococcal Vaccine Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
      • 8.7.7.2. Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
      • 8.7.7.3. Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. GSK plc
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Pfizer Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Merck KGaA
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Serum Institute of India Pvt. Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. CSL Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sanofi S.A
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Walvax Biotechnology Co., Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Beijing Minhai Biotechnology Co., Ltd
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Johnson & Johnson
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. AstraZeneca
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Novavax
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development

List of Tables:

  • Table 1 Global Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 2 Global Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 3 Global Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 4 North America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 5 North America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 6 North America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 7 U.S.: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 8 U.S.: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 9 U.S.: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 10 Canada: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 11 Canada: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 12 Canada: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 13 Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 14 Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 15 Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 16 UK: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 17 UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 18 UK: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 19 France: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 20 France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 21 France: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 22 Germany: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 23 Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 24 Germany: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 25 Italy: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 26 Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 27 Italy: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 28 Spain: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 29 Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 30 Spain: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 31 Netherlands: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 32 Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 33 Netherlands: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 34 Russia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 35 Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 36 Russia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 37 Rest of Europe: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 38 Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 39 Rest of Europe: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 40 Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 41 Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 42 Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 43 China: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 44 China: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 45 China: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 46 India: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 47 India: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 48 India: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 49 Malaysia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 50 Malaysia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 51 Malaysia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 52 Japan: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 53 Japan: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 54 Japan: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 55 Indonesia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 56 Indonesia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 57 Indonesia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 58 South Korea: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 59 South Korea: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 60 South Korea: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 61 Australia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 62 Australia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 63 Australia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 64 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 65 Rest of Asia Pacific: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 66 Rest of Asia Pacific: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 67 Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 68 Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 69 Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 70 Saudi Arabia: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 71 Saudi Arabia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 72 Saudi Arabia: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 73 UAE: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 74 UAE: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 75 UAE: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 76 Israel: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 77 Israel: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 78 Israel: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 79 South Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 80 South Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 81 South Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 82 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 83 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 84 Rest of Middle East & Africa: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 85 Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 86 Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 87 Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 88 Mexico: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 89 Mexico: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 90 Mexico: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 91 Brazil: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 92 Brazil: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 93 Brazil: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 94 Argentina: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 95 Argentina: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 96 Argentina: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)
  • Table 97 Rest of Latin America: Pneumococcal Vaccine Market, by Vaccine Type, 2019-2032 (USD billion)
  • Table 98 Rest of Latin America: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  • Table 99 Rest of Latin America: Pneumococcal Vaccine Market, by End User, 2019-2032 (USD billion)

List of Figures:

  • Figure 1. Global Pneumococcal Vaccine Market, 2019-2032 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Vaccine Type
  • Figure 7. Global Pneumococcal Vaccine Market, by Vaccine Type, 2023 & 2032 (USD billion)
  • Figure 8. Market by Product
  • Figure 9. Global Pneumococcal Vaccine Market, by Product, 2023 & 2032 (USD billion)
  • Figure 10. Market by End User
  • Figure 11. Global Pneumococcal Vaccine Market, by End User, 2023 & 2032 (USD billion)
  • Figure 12. Global Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
  • Figure 13. Strategic Analysis - Global Pneumococcal Vaccine Market